argenx SE's book value per share for the quarter that ended in Dec. 2024 was $90.49.
During the past 12 months, argenx SE's average Book Value Per Share Growth Rate was 36.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 28.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 45.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of argenx SE was 99.30% per year. The lowest was 24.50% per year. And the median was 38.60% per year.
argenx SE's current price is $649.67. Its book value per share for the quarter that ended in Dec. 2024 was $90.49. Hence, today's PB Ratio of argenx SE is 7.18.
During the past 13 years, the highest P/B Ratio of argenx SE was 10.43. The lowest was 3.02. And the median was 6.08.
argenx SE Book Value per Share Historical Data
The historical data trend for argenx SE's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of argenx SE's Book Value per Share
For the Biotechnology subindustry, argenx SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where argenx SE's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
argenx SE (NAS:ARGX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
argenx SE Book Value per Share Related Terms
Thank you for viewing the detailed overview of argenx SE's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARGX has been successfully added to your 